Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on why ctDNA remains a focus of research in colorectal cancer.
Back
The Evolving Role of ctDNA Testing in Colorectal Cancer
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss the evolving role of ctDNA in the management of colorectal cancer.
The Evolving Role of ctDNA Testing in Colorectal Cancer
Episodes
All
All
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on data from the GALAXY arm of CIRCULATE-Japan for ctDNA in stage II to IV CRC.
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how to approach conversations about ctDNA with patients with CRC.
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss findings for ctDNA in stage II/III CRC from the BESPOKE CRC trial.
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
2
CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease
3
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
4
Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer
5